Roche EGRF Outlook: Iressa Review Gives “Encouragement” To Tarceva
Executive Summary
Roche's outlook for Tarceva in non-small cell lung cancer received a "margin of encouragement" from the Iressa FDA advisory committee review, Pharmaceuticals Head William Burns said on a conference call Oct. 10